CXCL13/BLC/BCA-1 Antibody (53610) [Unconjugated]

801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." > 801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." title="Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) and Recombinant Mouse CXCL13/BLC/BCA-1 (Catalog # 470-BC). PVDF Membrane was probed with 1 µg/mL of Mouse Anti-Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # HAF007). A specific band was detected for CXCL13/BLC/BCA-1 at approximately 12 kDa (as indicated). This experiment was conducted under reducing conditions and using Immunoblot Buffer Group 3." />

Western blot shows 100 ng of Recombinant Human CXCL13/BLC/BCA-1 (Catalog # <a class=

801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND₅₀ is typically 0.3-0.9 µg/mL." > 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND₅₀ is typically 0.3-0.9 µg/mL." title="Recombinant Human CXCL13/BLC/BCA-1 (Catalog # 801-CX) chemoattracts the BaF3 mouse pro-B cell line transfected with human CXCR5 in a dose-dependent manner (orange line). The amount of cells that migrated through to the lower chemotaxis chamber was measured by Resazurin (Catalog # AR002). Chemotaxis elicited by Recombinant Mouse Anti-Human CXCL13/BLC/BCA-1 (0.05 µg/mL) is neutralized (green line) by increasing concentrations of Human CXCL13/BLC/BCA-1 Monoclonal Antibody (Catalog # MAB801). The ND₅₀ is typically 0.3-0.9 µg/mL." />

Recombinant Human CXCL13/BLC/BCA-1 (Catalog # <a class=

Relationship of different CD8+ TRM subset with B cells and TLS in CRC tumor tissues. (A) Volcano plot showing differentially expressed genes between DP CD8+ TRM subsets and SP CD8+ TRM subsets of the GSE108989 dataset. (B) The FFPE CRC tumor tissue slides from patients with CRC were stained with DAPI (blue), CD20 (green), CD8 (yellow), CD103 (orange), and CD69 (red). (C) Relationship between the proportion of different CD8+ TRM cells and the proportion of B cells in CRC tumor tissues detected by flow cytometry (n = 40) and relationship between the proportion of different CD8+ TRM cells and the count of B cells and the count and area of TLS in CRC tumor tissues detected by mIHC (n = 64). Statistical analysis was performed by Pearson correlation analysis. (D) Schematic overview of the transwell migration assay design. (E) B cell migration rate when cultured either alone or with different CD8+ TRM subsets (n = 10) and B cell migration rate when cultured with DP CD8+ TRM cells with or without anti-CXCL13 neutralizing antibody (n = 7). Statistical analysis was performed by non-parametric Wilcoxon’s matched-pairs tests and Friedman test with Dunn’s multiple comparisons test. (*p < 0.05; **p < 0.01) Image collected and cropped by CiteAb from the following open publication (//biosignaling.biomedcentral.com/articles/10.1186/s12964-024-01990-3), licensed under a CC-BY license. Not internally tested by R&D Systems.

801-CX) was serially diluted and captured by Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB801) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human CXCL13/BLC/BCA‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" > 801-CX) was serially diluted and captured by Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB801) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human CXCL13/BLC/BCA‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" title="Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # 801-CX) was serially diluted and captured by Mouse Anti-Human CXCL13/BLC/BCA‑1 Monoclonal Antibody (Catalog # MAB801) coated on a Clear Polystyrene Microplate (Catalog # DY990). Goat Anti-Human CXCL13/BLC/BCA‑1 Antigen Affinity-purified Polyclonal Antibody (Catalog # AF801) was biotinylated and incubated with the protein captured on the plate. Detection of the standard curve was achieved by incubating Streptavidin-HRP (Catalog # DY998)" />

Recombinant Human CXCL13/BLC/BCA‑1 (Catalog # <a class=

• Reactivity: Hu
• Applications: WB, B/N, ELISA(Cap)
• Clone: 53610
• Clonality: Monoclonal
• Host: Mouse
• Conjugate: Unconjugated

CXCL13/BLC/BCA-1 Antibody (53610) [Unconjugated] Summary

• Immunogen: E. coli-derived recombinant human CXCL13/BLC/BCA-1
  Val23-Arg94
  Accession # O43927
• Specificity: Detects human CXCL13/BLC/BCA-1 in ELISAs and Western blots. In ELISAs, no cross-reactivity with recombinant human (rh) CXCL1, rhCXCL2, rhCXCL3, rhCXCL8/IL‑8, rhCXCL10, rhCXCL9, rhCXCL12/SDF‑1 alpha , or rhCXCL12/SDF‑1 beta is observed. In Western blots, no cross‑reactivity with recombinant mouse CXCL13/BLC/BCA-1 is observed.
• Source: N/A
• Isotype: IgG1
• Clonality: Monoclonal
• Host: Mouse
• Gene: CXCL13
• Purity Statement: Protein A or G purified from hybridoma culture supernatant
• Endotoxin Note: <0.10 EU per 1 μg of the antibody by the LAL method.

Applications/Dilutions

• Dilutions:
  • ELISA Capture (Matched Antibody Pair) 2-8 ug/mL
  • ELISA Detection (Matched Antibody Pair) 0.1-0.4 ug/mL
  • ELISA Standard (Matched Pair)
  • Neutralization 0.3-0.9 ug/mL
  • Western Blot 1 ug/mL
• Application Notes: ELISA Detection: Human CXCL13/BLC/BCA-1 Biotinylated Antibody (Catalog number BAF801)
  Standard: Recombinant Human CXCL13/BLC/BCA-1 (Catalog number 801-CX)

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 6 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose. *Small pack size (SP) is supplied either lyophilized or as a 0.2 µm filtered solution in PBS.
• Preservative: No Preservative
• Reconstitution Instructions: Reconstitute at 0.5 mg/mL in sterile PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for CXCL13/BLC/BCA-1 Antibody (53610) [Unconjugated]

• ANGIE
• ANGIE2
• B cell-attracting chemokine 1
• B lymphocyte chemoattractant
• BCA1
• BCA-1
• BCA1B-cell chemoattractant
• BCA-1CXC chemokine BLC
• B-cell-homing chemokine (ligand for Burkitt's lymphoma receptor-1)
• BLC
• BLCSmall-inducible cytokine B13
• BLR1L
• B-lymphocyte chemoattractant
• chemokine (C-X-C motif) ligand 13 (B-cell chemoattractant)
• chemokine (C-X-C motif) ligand 13
• C-X-C motif chemokine 13
• CXCL13
• SCYB13
• SCYB13B-cell-attracting chemokine 1
• small inducible cytokine B subfamily (Cys-X-Cys motif), member 13 (B-cellchemoattractant)

Background

CXCL13, also known as B-lymphocyte chemoattractant (BLC), is a CXC chemokine that is constitutively expressed in secondary lymphoid organs. BCA-1 cDNA encodes a protein of 109 amino acid residues with a leader sequence of 22 residues. Mature human BCA-1 shares 64% amino acid sequence similarity with the mouse protein and 23-34% amino acid sequence identity with other known CXC chemokines. Recombinant or chemically synthesized BCA-1 is a potent chemoattractant for B lymphocytes but not T lymphocytes, monocytes or neutrophils. BLR1, a G protein-coupled receptor originally isolated from Burkitt’s lymphoma cells, has now been shown to be the specific receptor for BCA-1. Among cells of the hematopoietic lineages, the expression of BLR1, now designated CXCR5, is restricted to B lymphocytes and a subpopulation of T helper memory cells. Mice lacking BLR1 have been shown to lack inguinal lymph nodes. These mice were also found to have impaired development of Peyer’s patches and defective formation of primary follicles and germinal centers in the spleen as a result of the inability of B lymphocytes to migrate into B cell areas.

1. Gunn, M.D. et al. (1998) Nature, 391:799.
2. Legler, D.F. et al. (1998) J. Exp. Med. 187:655.
3. Forster, R. et al. (1996) Cell 87:1037.

Limitations

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Publications for CXCL13/BLC/BCA-1 Antibody (MAB801)(17)

Publications using MAB801

• Samson, C;Thiolat, A;Moktefi, A;Cohen, JL;Pilon, C;Grimbert, P; Belatacept inhibit human B cell germinal center development in immunodeficient mice Scientific reports 2023-08-24 [PMID: 37620431] (IHC, Mouse)
• Shu-Jyuan Chang, Chia-Te Chao, Aij-Lie Kwan, Chee-Yin Chai The Diagnostic Significance of CXCL13 in M2 Tumor Immune Microenvironment of Human Astrocytoma Pathology and Oncology Research 2022-04-28 [PMID: 35570844]
• A Satou, T Tabata, H Miyoshi, K Kohno, Y Suzuki, D Yamashita, K Shimada, T Kawasaki, Y Sato, T Yoshino, K Ohshima, T Takahara, T Tsuzuki, S Nakamura Methotrexate-associated lymphoproliferative disorders of T-cell phenotype: clinicopathological analysis of 28 cases Mod. Pathol., 2019-04-05;0(0):. 2019-04-05 [PMID: 30952973] (IHC-P, Human)
• R Muto, H Miyoshi, K Sato, T Furuta, H Muta, K Kawamoto, E Yanagida, K Yamada, K Ohshima Epidemiology and secular trends of malignant lymphoma in Japan: Analysis of 9426 cases according to the World Health Organization classification Cancer Med, 2018-10-11;0(0):. 2018-10-11 [PMID: 30311404] (IHC, Human)
• DS Thommen, VH Koelzer, P Herzig, A Roller, M Trefny, S Dimeloe, A Kiialainen, J Hanhart, C Schill, C Hess, S Savic Prin, M Wiese, D Lardinois, PC Ho, C Klein, V Karanikas, KD Mertz, TN Schumacher, A Zippelius A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small-cell lung cancer treated with PD-1 blockade Nat. Med., 2018-06-11;0(0):. 2018-06-11 [PMID: 29892065] (Flow Cytometry, Human)
• LA Aqrawi, M Ivanchenko, A Björk, JI Ramírez Se, J Imgenberg-, M Kvarnström, P Haselmayer, JL Jensen, G Nordmark, K Chemin, K Skarstein, M Wahren-Her Diminished CXCR5 expression in peripheral blood of patients with Sj�gren&#039;s syndrome may relate to both genotype and salivary gland homing Clin. Exp. Immunol., 2018-03-24;0(0):. 2018-03-24 [PMID: 29453859] (IHC-P, Human)
• A Asai, Y Tsuchimoto, H Ohama, S Fukunishi, Y Tsuda, M Kobayashi, K Higuchi, F Suzuki Host antitumor resistance improved by the macrophage polarization in a chimera model of patients with HCC Oncoimmunology, 2017-03-03;6(4):e1299301. 2017-03-03 [PMID: 28507807] (ICC, Human)
• Mika Komori, Yen Chih Lin, Irene Cortese, Andrew Blake, Joan Ohayon, Jamie Cherup et al. Insufficient disease inhibition by intrathecal rituximab in progressive multiple sclerosis Annals of Clinical and Translational Neurology 2016-03-01 [PMID: 27042677]
• Seok Jin Kim, Kyung Ju Ryu, Mineui Hong, Young Hyeh Ko, Won Seog Kim The serum CXCL13 level is associated with the Glasgow Prognostic Score in extranodal NK/T-cell lymphoma patients Journal of Hematology & Oncology 2015-12-01 [PMID: 25966773]
• Klimatcheva E, Pandina T, Reilly C, Torno S, Bussler H, Scrivens M, Jonason A, Mallow C, Doherty M, Paris M, Smith E, Zauderer M CXCL13 antibody for the treatment of autoimmune disorders. BMC Immunol, 2015-02-12;16(0):6. 2015-02-12 [PMID: 25879435] (Direct ELISA, Human)
• Komori M, Blake A, Greenwood M et al. Cerebrospinal fluid markers reveal intrathecal inflammation in progressive multiple sclerosis. Ann Neurol 7/1/2015 [PMID: 25808056]
• Edwards , Keith R, Goyal , Jaya, Plavina , Tatiana, Czerkowicz , Julie, Goelz , Susan, Ranger , Ann, Cadavid , Diego, Browning , Jeffrey Feasibility of the use of combinatorial chemokine arrays to study blood and CSF in multiple sclerosis. PLoS ONE, 2013-11-20;8(11):e81007. 2013-11-20 [PMID: 24278364] (Immuno-PCR, Human)
• Kotaro Kitaya, Tadahiro Yasuo Aberrant expression of selectin E, CXCL1, and CXCL13 in chronic endometritis Modern Pathology 2010-08-01 [PMID: 20495539]
• Panse J, Friedrichs K, Marx A, Hildebrandt Y, Luetkens T, Bartels K, Horn C, Stahl T, Cao Y, Milde-Langosch K, Niendorf A, Kroger N, Wenzel S, Leuwer R, Bokemeyer C, Hegewisch-Becker S, Atanackovic D Chemokine CXCL13 is overexpressed in the tumour tissue and in the peripheral blood of breast cancer patients. Br. J. Cancer, 2008-09-16;99(6):930-8. 2008-09-16 [PMID: 18781150] (IHC-P, Western Blot, Human)
• Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood, 2007-07-25;110(9):3316-25. 2007-07-25 [PMID: 17652619] (IHC-P, Human)
• Lisignoli G, Cristino S, Piacentini A, Cavallo C, Caplan AI, Facchini A Hyaluronan-based polymer scaffold modulates the expression of inflammatory and degradative factors in mesenchymal stem cells: Involvement of Cd44 and Cd54. J. Cell. Physiol., 2006-05-01;207(2):364-73. 2006-05-01 [PMID: 16331675] (ELISA Development, Human)
• Lisignoli G, Cristino S, Toneguzzi S, Grassi F, Piacentini A, Cavallo C, Facchini A, Mariani E IL1beta and TNFalpha differently modulate CXCL13 chemokine in stromal cells and osteoblasts isolated from osteoarthritis patients: evidence of changes associated to cell maturation. Exp. Gerontol., 2004-04-01;39(4):659-65. 2004-04-01 [PMID: 15050303] (IHC-P, Human)

Bioinformatics

• Gene Symbol: CXCL13
• Uniprot:
  • O43927()